Background. Artemisinin-based combination therapies (ACTs) have been widely adopted as first-line agents to treat uncomplicated falciparum malaria due to their activity against multidrug resistant parasites. ACTs may also disrupt transmission through a direct antigametocyte effect, but the extent of this effect is uncertain. We assessed the evidence for and estimated the effects of the most widely-deployed ACT, artemether-lumefantrine (AL), relative to non-ACTs on gametocyte clearance and transmission interruption.
other widely-used ACTs for reducing gametocyte carriage and disrupting transmission [13] [14] [15] [16] . The objective of this review is to systematically identify and synthesize the evidence for and quantify the effects of AL relative to non-ACTs on gametocyte carriage and transmission interruption in individuals with uncomplicated falciparum malaria.
METHODS

Eligibility Criteria
We included randomized controlled trials (RCTs) that compared AL (6-dose regimen) to one or more non-ACT regimens for gametocyte clearance or mosquito infectivity. We included studies in endemic regions of participants of any age with a diagnosis of uncomplicated falciparum malaria. We excluded studies of severe malaria and non-falciparum malaria, and trials in migrants, displaced peoples, travelers, and military personnel.
Outcomes
The primary outcomes were the proportion of study participants with circulating gametocytes 7 days after initiation of treatment, measured by microscopy, and the proportion of mosquitoes that developed gut oocysts in feeding studies at any day. Secondary outcomes included the proportion of study participants with circulating gametocytes at post-treatment day 14, mean duration of gametocyte carriage, mean gametocyte density, area under the curve (AUC) of gametocyte density, and proportion of participants in feeding studies who were infectious to mosquitoes.
Search Strategy
We designed an electronic search strategy using terms related to "malaria" and "antimalarial drugs" (Supplementary Table 1 ). We applied a filter for RCTs to electronic databases for which that feature was available. We searched PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov on February 5, 2016 , and manually searched references of relevant papers. The search was not limited by year or language.
Data Extraction
We extracted data pertaining to study design, eligibility criteria, baseline characteristics of the study groups, co-administered interventions, features of the study setting including transmission intensity and locale (rural, urban, peri-urban), duration of follow-up, and attrition. We extracted gametocyte and mosquito-feeding outcomes from text or tables, or estimated them from figures when necessary. At time points for which a denominator was not reported, we estimated it as the sample size at the previous time point if available, otherwise as the initial sample size. Where continuous variables were presented as medians, we assumed a normal distribution and converted medians to means. One trial included a 4-dose AL group, but only the standard 6-dose AL group was considered in analyses [17] . For the single study that performed polymerase chain reaction (PCR) for gametocytes [18] , we only extracted results of microscopy in order to maintain comparability across trials.
Assessment of Risk of Bias
We used the Cochrane Collaboration tool for risk of bias assessments of individual studies [19] . We considered selection, performance, detection, attrition, and reporting biases, graded independently by two authors as low risk, high risk, or unclear risk.
Analysis
We qualitatively assessed the comparability of characteristics and designs of included trials. We assessed statistical heterogeneity among the included trials through visual inspection of forest plots and computation of the I 2 statistic. By convention, I 2 values of 0.3-0.6 were interpreted as evidence of moderate heterogeneity, and values >0.6 as considerable heterogeneity [20] . When no substantial clinical, methodological, or statistical heterogeneity was present, we conducted meta-analyses using a random-effects model in RevMan 5.0 (The Cochrane Collaboration). We conducted prespecified subgroup analyses by age (≤5 and >5 years of age), comparator drug (amodiaquine plus sulfadoxine/sulfalene-pyrimethamine, AQ-SP; and chloroquine plus sulfadoxine-pyrimethamine, CQ-SP), and geographic region (Africa and South/Southeast Asia). We assessed small-study effects by visual inspection of funnel plots for asymmetry. We performed a sensitivity analysis excluding studies with high or unclear risk of detection bias, based on whether study microscopists were masked.
RESULTS
Study Selection
We identified 7602 unique records from our searches and included 22 RCTs in the systematic review ( Figure 1 ). Fifteen studies reported sufficient data for inclusion in meta-analyses.
Study Characteristics
Of the 22 included RCTs, only 2 were designed explicitly to evaluate malaria transmission [18, 21] . All others reported gametocyte and mosquito infectivity results as secondary outcomes. The trials were predominantly done in children; only 3 included adults [22] [23] [24] . Eight recruited children <5 years of age [25] [26] [27] [28] [29] [30] [31] [32] . Most trials were conducted in sub-Saharan Africa (17 out of 22), the remainder in South and Southeast Asia.
The trials examined a total of 60 treatment groups, of which 23 groups received AL, 10 groups ACTs other than AL, and 27 groups non-ACTs (Table 1) . Non-ACT regimens mainly comprised mono-or combination therapies of AQ (10 trials), CQ (7 trials), and SP (18 trials). Dosing schedules for the non-ACT groups were standard. Two trials reported co-interventions: 1 administered iron supplementation [33] , and 1 administered the gametocytocide primaquine to study participants with gametocytemia at any follow-up visit, which resulted in a greater number of participants in the non-ACT group receiving the drug [22] .
Seventeen trials reported the proportion of participants with gametocytemia at post-treatment day 7 and/or 14, and 2 reported results of mosquito feeding assays. Additional gametocyte-related measures included mean or median gametocyte density [21] [22] [23] [34] [35] [36] , cumulative prevalence of gametocytemia [22, 37] , mean duration of gametocytemia [21] , probability of remaining gametocyte-free [34] , gametocyte clearance rate [31], AUC of gametocyte density [34] , ratio of means of gametocyte density [21] , total person-time with gametocytes [21, 30] , and mean gametocyte sex ratio [34] . One trial restricted its follow-up gametocyte measurements only to participants who were gametocytemic at baseline [34] . Every trial included genotyping (e.g., pfmsp1 and pfmsp2 alleles) to distinguish reinfection from recrudescence in participants with recurrent parasitemia, but none provided information relating new or recrudescent asexual parasitemia to the presence of gametocytes.
Risk of Bias of Included Trials
There was an overall low risk of bias within trials ( Table 2,  Supplementary Table 2) . Outcome assessments were unmasked in 2 trials [25, 38] and not described in 8 others [17, 21, 24, 27, 33, 35, 37, 39] . Attrition bias was low, with retention rates >90% in nearly all trials; 3 trials reported losses to follow-up >20% in one or more treatment groups [21, 26, 33] . A funnel plot of effect estimates from studies that reported 7-and 14-day gametocyte prevalence displayed a near-symmetric distribution about the pooled estimate, indicating low evidence of smallstudy effects ( Figure 2 ).
Relative Effects of Artemether-lumefantrine
We found that AL significantly reduced the odds of gametocyte carriage one week after treatment compared to non-ACTs (OR 0.09; 95% confidence interval [CI], 0.06-0.15, I 2 = 0.60, P < .01; 15 trials) ( Figure 3 ). The proportion of participants with gametocytemia at one week ranged from 0-19% in the AL groups to 1-83% in the non-ACT groups. High statistical heterogeneity precluded pooled analysis of results at two weeks (I 2 = 0.75; 15 trials), but 9 of the 15 trials showed AL to be significantly better than non-ACTs and, among the remainder, all except 2 trended toward AL ( Figure 4 ). Trials that reported other gametocyte outcomes all showed fewer gametocytes or faster clearance of gametocytes among AL treatment groups than non-ACT groups, though not all results attained statistical significance (data not shown). The only trial that examined gametocyte sex ratios was limited by small sample size, and did not detect a statistically significant difference between AL and the non-ACT comparator [33] . We performed a sensitivity analysis including only trials that reported a procedure for masking study microscopists during gametocyte assessments. The sensitivity analysis showed similar results to the primary meta-analysis (OR 0.07; 95% CI, 0.04-0.13; I 2 = 0.52, P < .01;
trials).
We identified 2 trials that carried out mosquito feeding assays [18, 21] . One trial performed assessments on post-treatment day 7 in participants treated with either AL or CQ-SP [21] , the other on day 14 in participants receiving AL, SP, or AQ-SP [18] . Both demonstrated significantly fewer infected mosquitoes among those fed on blood from AL-treated participants compared to non-ACT-treated participants (day 7: OR 0.06; 95% CI, 0.00-0.47; P < .01; day 14: OR 0.56; 95% CI, 0.36-0.88; P = .01).
Subgroup Analyses
We performed subgroup analyses by participant age, comparator drug, and geographic region (Table 3) . We found no detectable difference in gametocyte clearance between The combination of artemether's direct antigametocyte action and faster killing of P. falciparum asexual stages likely explains the decreased gametocyte carriage and mosquito infectivity of AL-treated participants compared to non-ACT-treated participants [9] [10] [11] . Direct activity against early-stage gametocytes precludes maturation to transmissible late-stage gametocytes, and clearance of asexual stages is hypothesized to deplete the pool from which gametocytes arise [40] . Artemisinins also may interrupt gametocyte progression through sporogony once they are taken up by vector mosquitoes [12] . The non-artemisinin component of AL, lumefantrine, also may have antigametocyte and sporonticidal action [41] [42] [43] . Subgroup analyses illustrated a hierarchy of antigametocyte efficacy among specific comparators (AL > AQ-SP > CQ-SP), consistent with results previously reported in the literature [44] . The results of the trial that administered the gametocytocide primaquine to participants with gametocytemia at any follow-up visit were consistent with those observed in other trials despite more in the non-ACT group receiving primaquine, offering a conservative estimate of the relative effect of AL [22] .
Gametocytemia is an imperfect marker of infectivity; infected individuals can remain infective after gametocytes fall below microscopically detectable concentrations, and factors in addition to absolute counts, such as gametocyte sex ratios, may modulate transmission [45] [46] [47] . Mosquito feeding assays remain the most direct means of assessment of transmissibility, but these are challenging to do. Only 2 trials included feeding assays [18, 21] . They showed that blood from AL-treated participants reduced infectivity to mosquitoes on post-treatment days 7 and 14 compared to blood from those treated with non-ACT regimens. The single trial that correlated treatment regimens to gametocyte sex ratios found no difference between AL and the non-ACT comparator, AQ-SP, but its small number of gametocytemic individuals may have led to insufficient statistical power to detect a difference [34] .
Age-related immunity is believed to contribute to gametocyte clearance [3] , and we hypothesized it would influence the observed effect sizes in children of different age groups. However, in subgroup meta-analyses comparing trials of children above and below 5 years of age, we found no significant difference in gametocyte clearance. This finding was unexpected, as older children have been shown to display increased immune responses directed against gametocytes compared to younger children [3, 48] . Surprisingly, field trials suggest gametocyte carriage may persist longer in older than younger children [49] . Immune-mediated clearance of gametocytes remains incompletely characterized, and age-related immunity appears to differ in regard to clearance of gametocytes and that of asexual parasites [49] [50] [51] .
Impressive gains in malaria control and elimination made over the last decade are threatened by political instability, repercussions of climate change, stagnating funding, rising insecticide resistance, and the prospect of artemisinin-resistant parasites spreading to sub-Saharan Africa [2, 52] . These threats can be mitigated by optimizing our use of available tools. To this end, future trials of the relative effects of different ACTs on transmission of parasites to mosquitoes will be helpful. A network meta-analysis that extends the scope of the present study to compare the relative effects of different ACTs to each other and to non-ACTs would be informative.
Beyond malaria case management, the relative transmission impacts of antimalarials may have relevance for other drug deployment strategies. Treated symptomatic cases continue to contribute to the infectious reservoir due to persistent circulation of gametocytes for a duration that varies by therapy. But asymptomatic cases, a heterogeneous group, also contribute to the infectious reservoir [53] [54] [55] . Asymptomatic cases are targeted by intermittent preventive therapy, mass drug administration, and screen-and-treat programs. Studies and mathematical models of the comparative effects of these interventions using different antimalarial drugs could further aid in optimizing malaria control strategies.
There were limitations to this review. We only included trials with an AL treatment group, limiting the generalizability of our results to other ACTs. We compared AL to a number of different regimens, limiting our ability to tease out effects of individual drugs. Only 2 trials were designed to assess treatment impact on transmission. Misclassification bias was potentially high, due to reliance mainly on microscopy rather than more sensitive PCRbased methods of gametocyte detection. Although all included Abbreviations: AQ, amodiaquine; CI, confidence interval; CQ, chloroquine; OR, odds ratio; SP, sulfadoxine/sulfalene-pyrimethamine.
trials used genotyping to distinguish treatment failure from reinfection, none reported the association between gametocyte outcomes and reinfection or recrudescence; it was therefore not possible to distinguish among persistent gametocytemia following initial treatment, recrudescent gametocytemia, or new gametocytemia due to reinfection. Despite these limitations, the large effect size for AL strongly suggests that it offers benefit over non-ACT regimens in abating malaria transmission.
CONCLUSIONS
AL is superior to non-ACT regimens in reducing gametocyte carriage and interrupting transmission in individuals with uncomplicated falciparum malaria. In a meta-analysis of 15 trials, treatment with AL led to a 91% reduction in the odds of gametocytemia at one week compared to non-ACTs. Two trials showed reduction in transmission to mosquitoes at 1 and 2 weeks post-treatment. The benefit of transmission interruption conferred by ACTs has relevance for policy makers planning optimal utilization of currently available control and elimination tools, including the use of ACTs for malaria treatment and chemoprevention.
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